{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:22:38Z","timestamp":1783981358576,"version":"3.55.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.clim.2005.01.011","type":"journal-article","created":{"date-parts":[[2005,3,11]],"date-time":"2005-03-11T12:26:46Z","timestamp":1110544006000},"page":"216-223","source":"Crossref","is-referenced-by-count":80,"title":["IL-6 levels predict disease variant and extent of organ involvement in patients with mastocytosis"],"prefix":"10.1016","volume":"115","author":[{"given":"Knut","family":"Brockow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cem","family":"Akin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean D.","family":"Metcalfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2005.01.011_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-198811000-00001","article-title":"Systemic mast cell disease. Analysis of 58 cases and literature review","volume":"67","author":"Travis","year":"1988","journal-title":"Medicine"},{"key":"10.1016\/j.clim.2005.01.011_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0889-8588(05)70296-3","article-title":"Hematologic aspects of systemic mastocytosis","volume":"14","author":"Parker","year":"2000","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.clim.2005.01.011_bib3","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0889-8588(05)70297-5","article-title":"Lymphoid tissues and the immune system in mastocytosis","volume":"14","author":"Mekori","year":"2000","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.clim.2005.01.011_bib4","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428190009058500","article-title":"Clinical and biologic diversity of leukemias occurring in patients with mastocytosis","volume":"37","author":"Sperr","year":"2000","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.clim.2005.01.011_bib5","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.clim.2005.01.011_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0145-2126(01)00046-7","article-title":"Mastocytosis: molecular mechanisms and clinical disease heterogeneity","volume":"25","author":"Metcalfe","year":"2001","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clim.2005.01.011_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1067\/mai.2002.120524","article-title":"Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase","volume":"109","author":"Brockow","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.clim.2005.01.011_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1159\/000063858","article-title":"Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients","volume":"128","author":"Theoharides","year":"2002","journal-title":"Int. Arch. Allergy Immunol."},{"key":"10.1016\/j.clim.2005.01.011_bib9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0167-5699(90)90173-7","article-title":"Biological and clinical aspects of interleukin 6","volume":"11","author":"Hirano","year":"1990","journal-title":"Immunol. Today"},{"key":"10.1016\/j.clim.2005.01.011_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4049\/jimmunol.155.1.297","article-title":"Heterogeneity of human mast cells based on cytokine content","volume":"155","author":"Bradding","year":"1995","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2005.01.011_bib11","first-page":"583","article-title":"The soluble IL-6 receptors: serum levels and biological function","volume":"47","author":"Montero-Julian","year":"2001","journal-title":"Cell. Mol. Biol. (Noisy-le-Grand)"},{"key":"10.1016\/j.clim.2005.01.011_bib12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3181\/00379727-213-44055","article-title":"Interleukin-6-type cytokines in vivo: regulated bioavailability","volume":"213","author":"Sehgal","year":"1996","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.clim.2005.01.011_bib13","doi-asserted-by":"crossref","first-page":"11924","DOI":"10.1073\/pnas.90.24.11924","article-title":"Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6","volume":"90","author":"Tamura","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.clim.2005.01.011_bib14","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.V82.4.1120.1120","article-title":"Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130","volume":"82","author":"Narazaki","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.clim.2005.01.011_bib15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1172\/JCI114749","article-title":"Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice","volume":"86","author":"Brandt","year":"1990","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2005.01.011_bib16","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1172\/JCI114046","article-title":"Interleukin 6 gene expression in normal and neoplastic B cells","volume":"83","author":"Freeman","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2005.01.011_bib17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.V74.2.798.798","article-title":"A possible autocrine role for interleukin-6 in two lymphoma cell lines","volume":"74","author":"Yee","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.clim.2005.01.011_bib18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1182\/blood.V73.5.1279.1279","article-title":"Constitutive expression of the interleukin-6 gene in chronic lymphocytic leukemia","volume":"73","author":"Biondi","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.clim.2005.01.011_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1172\/JCI114186","article-title":"Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control","volume":"84","author":"Oster","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2005.01.011_bib20","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1172\/JCI114392","article-title":"Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias","volume":"84","author":"Bataille","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2005.01.011_bib21","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863","article-title":"Interleukin-6 in human multiple myeloma","volume":"85","author":"Klein","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clim.2005.01.011_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0609.2001.00152.x","article-title":"Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenstrom's macroglobulinemia","volume":"66","author":"Hatzimichael","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.clim.2005.01.011_bib23","series-title":"World health organization classification of tumors. Pathology and genetics of tumors of hematopoietic and lymphoid tissue","first-page":"293","article-title":"Mastocytosis","author":"Valent","year":"2001"},{"key":"10.1016\/j.clim.2005.01.011_bib24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1182\/blood.V96.4.1267","article-title":"Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology","volume":"96","author":"Akin","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clim.2005.01.011_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1067\/mjd.2003.98","article-title":"Assessment of the extent of cutaneous involvement in children and adults with mastocytosis: relationship to symptomatology, tryptase levels, and bone marrow pathology","volume":"48","author":"Brockow","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.clim.2005.01.011_bib26","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/0197-4580(94)90066-3","article-title":"Interleukin-6 and selected plasma proteins in healthy persons of different ages","volume":"15","author":"Hager","year":"1994","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.clim.2005.01.011_bib27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0531-5565(00)00220-5","article-title":"Serum interleukin-6, soluble interleukin-6 receptor and soluble gp130 exhibit different patterns of age- and menopause-related changes","volume":"36","author":"Giuliani","year":"2001","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.clim.2005.01.011_bib28","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI118337","article-title":"The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis","volume":"96","author":"Schwartz","year":"1995","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2005.01.011_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4049\/jimmunol.157.1.343","article-title":"Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells","volume":"157","author":"Saito","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2005.01.011_bib30","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1182\/blood.V86.10.3705.bloodjournal86103705","article-title":"Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells","volume":"86","author":"Yanagida","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clim.2005.01.011_bib31","first-page":"52","article-title":"Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma","volume":"20","author":"Filella","year":"1996","journal-title":"Cancer Detect. Prev."},{"key":"10.1016\/j.clim.2005.01.011_bib32","first-page":"2069","article-title":"Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies","volume":"24","author":"Uson","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.clim.2005.01.011_bib33","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1084\/jem.183.4.1399","article-title":"The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6","volume":"183","author":"Peters","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2005.01.011_bib34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.clim.2005.01.011_bib35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1398-9995.1990.tb00945.x","article-title":"Mastocytosis and atopy: a study of 33 patients with urticaria pigmentosa","volume":"45","author":"Muller","year":"1990","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2005.01.011_bib36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/0145-2126(91)90068-5","article-title":"Leukocytosis in mice following long-term reconstitution with genetically-modified bone marrow cells constitutively expressing interleukin 1 alpha or interleukin 6","volume":"15","author":"Hawley","year":"1991","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clim.2005.01.011_bib37","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1084\/jem.176.4.1149","article-title":"Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus","volume":"176","author":"Hawley","year":"1992","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2005.01.011_bib38","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1309\/Q2WJ-46CL-YRFT-M5JF","article-title":"Bone marrow mast cell morphologic features and hematologic dyspoiesis in systemic mast cell disease","volume":"116","author":"Stevens","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.clim.2005.01.011_bib39","first-page":"411","article-title":"Correlation of synovial fluid interleukin 6 (IL-6) activities with IgG concentrations in patients with inflammatory joint disease and osteoarthritis","volume":"7","author":"Hermann","year":"1989","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.clim.2005.01.011_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000203682","article-title":"Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity","volume":"97","author":"Papadaki","year":"1997","journal-title":"Acta Haematol."},{"key":"10.1016\/j.clim.2005.01.011_bib41","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1002\/eji.200425268","article-title":"High levels of neutralizing IL-6 autoantibodies in 0.1% of apparently healthy blood donors","volume":"34","author":"Galle","year":"2004","journal-title":"Eur. J. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661605000367?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661605000367?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T01:10:56Z","timestamp":1706058656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661605000367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S1521661605000367"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2005.01.011","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}